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Abstract Chemotherapy and radiotherapy often result in
reduced fertility in cancer patients. With increasing sur-
vival rates, fertility is an important quality-of-life concern
for many young cancer patients. Around 70–75% of young
cancer survivors are interested in parenthood but the
numbers of patients who access fertility preservation
techniques prior to treatment are significantly lower.
Moreover, despite existing guidelines, healthcare profes-
sionals do not address fertility preservation issues ade-
quately. There is a critical need for improvements in
clinical care to ensure patients are well informed about
infertility risks and fertility preservation options and to
support them in their reproductive decision-making prior to
cancer treatment.
Keywords Cancer patients  Fertility preservation 
Cryopreservation  Infertility  Adolescent/child cancer
Introduction
When a patient is facing with cancer, the main concern is,
definitively, the cure of the disease. However, the
increasing large number of patients and long-term sur-
vivors oblige to discuss with them, before treatment would
have been initiated, the possibility of losing fertility after
cancer therapies. In this guideline, we will present global
trend in this field, the consequence of surgery, radiotherapy
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or chemotherapy, and the main strategies to avoid sterility
in patients, with the pros and cons of different methods.
Cancer in young people
Patients aged 15–39 years old at the diagnosis constitute the
adolescent and young adult cancer survivorship population,
which includes approximately 700,000 patients diagnosed
each year, or 2% of all invasive cancers diagnosed in the
United States [1]. In Europe, an estimated 130,500 new
cancer diagnoses (non-melanoma skin cancers being exclu-
ded) are made per year in this subset [2]. The most common
types of cancer occurring in this group included: lymphoma
(21%), melanoma (15%), cancer of the male genital system
(11%), cancer involving the endocrine system (11%) and
cancer of the female genital tract (9%).
Cancer therapy often affects reproductive organs, leading
to impaired pubertal development, hormonal regulation,
fertility, and sexual function, affecting quality of life.
Table 1 shows the increased risk of infertility; however, the
ultimate impact on reproductive potential depends on the age
of the patient, the type, dose and duration of treatment, and
the idiosyncrasies of the individual and the cancer [3, 4].
Fertility preservation interventions, is it a demand
of cancer patients?
All patients of reproductive age diagnosed with cancer
should be informed of the potential for gonadal toxicity and
the options to preserve future fertility. Cancer-related
infertility has a negative influence on the quality of life [5].
International guidelines recommend previous treatment
discussion with the patient about infertility, fertility
preservation options, and needs for contraception prior to
initiating therapy [6]. However, this practice has not
become routine and the number of patients receiving this
information is insufficient [5, 6].
Patients who choose the option of fertility preservation
should be referred to appropriate reproductive specialists
within 24 h and to a mental health professional to assist
with complex decision-making if they needed [5]. A fol-
low-up appointment should also be offered once the patient
has completed treatment to allow discussion and informa-
tion about the clinical use of stored gametes (if appropriate)
[3, 4].
Considering the above, discussion about their risk of
infertility prior to initiating cancer treatment is a manda-
tory intervention for patients of reproductive age (Evi-
dence IA).
Fertility preservation options for local treatment
of cancer
Fertility preservation options in patients undergoing
radiotherapy
The gonads are very sensitive to radiotherapy, especially in
prepubertal. Cranial irradiation also may induce infertility
by disruption of the hypothalamic-pituitary-gonadal axis
and disturbance normal hormonal secretion. [7]. Table 2
shows the risk of infertility after radiotherapy. Shielding of
the gonadal area is the standard procedure for reducing
scatter radiation to the reproductive organs and to preserve
Table 1 Conditions with increased risk of infertility
Risk of infertility Males Females
High risk ([80% risk of permanent
amenorrhea in women; prolonged
azoospermia in men)






BCNU (1 g/m2) and CCNU
(500 mg/m2)
Hematopoietic stem cell transplantation with cyclophosphamide
Total-body irradiation or cyclophosphamide/busulfan
External beam radiation to a field that includes the ovaries
CMF, CEF, CAF, TAC 9 6 cycles in women C40 years
Intermediate risk (40– 60% risk of
permanent amenorrhea in women;







CMF, CEF, CAF, TAC 9 6 cycles in women age 30–39
AC 9 4 cycles in women C40 years
AC or EC 9 4 ? Taxanes
AC adriamycin, cyclophosphamide, BEACOPP Bleomycin, Etoposide , Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisona,
CAF Cyclophosphamide , Adriamycin, 5-fluoruracil, CEF Cyclophosphamide, Epirrubicin, 5-fluoruracil, CMF cyclophosphamide, Methotrexate,
5-fluoruracil, TAC Docetaxel, Adriamycin, Cyclophosphamide
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fertility. In pelvic irradiation, surgical ovarian transposition
has been shown to reduce the risk of ovarian failure, in
adult patients. Other cryopreservation techniques may be
considered prior to radiotherapy administration [7].
Fertility preservation options in patients undergoing
surgery
Surgical techniques for preserving reproductive systems
without compromising survival are relatively recent and
procedures are still evolving. Indications for conservative
surgery include generally well-differentiated, low-grade
tumor in its early stages, or low malignant potential [8].
Table 3 shows the options to fertility-sparing interventions
in female patients.
Fertility preservation when coping with systemic
treatment
Toxicity of different schedules of chemotherapy
and hormonotherapy
Regimens used in cancer patients provoke gonadal toxicity
in both sexes. In adult women, the possibility of offspring
is particularly low, especially in hematological and breast
cancer survivors [4, 6, 9–11]. Patients with breast cancer
have the lowest chance of subsequent pregnancy, about
70% compared to the general population [13, 15]. Gonadal
toxicity depends on age and chemotherapy schedule
received [9–12, 14, 15] (Table 4).
Table 2 Risk of prolonged azoospermia in males or amenorrhea in females after radiotherapy
High risk Intermediate risk
Total-body irradiation for bone marrow transplant/stem cell
transplant
Testicular radiation dose[2.5 Gy in adult men
Testicular radiation dose C6 Gy in prepubertal boys
Pelvic or whole abdominal radiation dose C6 Gy in adult women
Pelvic or whole abdominal radiation dose C10 Gy in postpubertal
girls
Pelvic or whole abdominal radiation dose C15 Gy in prepubertal
girl
Testicular radiation dose 1–6 Gy from scattered pelvic or abdominal
radiation
Pelvic or whole abdominal radiation dose 5–10 Gy in postpubertal girls
Pelvic or whole abdominal radiation dose 10–15 Gy in prepubertal girls
Craniospinal radiotherapy dose C25 Gy
Modified from Rodriguez-Wallberg et al. [7]
Table 3 Options to fertility-sparing interventions in female patients undergoing surgery





Oncologic outcome is comparable with the
more radical approach of removing both
ovaries and the uterus
Recurrence 0–20 versus 12–58% when only
cystectomy was performed
Pregnancies have been reported with
a favorable obstetric outcome
Ovarian epithelial cancer
stage I, grade 1
Unilateral
oophorectomy
7% recurrence of the ovarian malignancy and
5% deaths
Pregnancies have been reported with
a favorable obstetric outcome





Risk of recurrence similar to historical controls Pregnancies have been reported and
favorable obstetric outcome




Rates of recurrence and mortality are
comparable with those described for similar
cases treated by radical hysterectomy or
radiation therapy
Spontaneous pregnancies described in
up to 70%. Risk of second-trimester
pregnancy loss and preterm delivery
Endometrial adenocarcinoma








Recurrence rate 30–40%; 5% recurrence during
progesterone treatment
Pregnancies have been reported
Modified from Rodriguez-Wallberg et al. [7]
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Methods to preserve fertility in males with cancer
The options for preservation of fertility in males include
[16, 17]:
1. Sperm cryopreservation [18]: semen cryopreserva-
tion with one to three samples collection is recom-
mended (Evidence IIIA). Sperm collection is
recommended before star treatment, because there is
a potential risk. Methods such as intracytoplasmic
sperm injection [19] allow the future use of a very
limited amount of sperm. When patients are unable to
ejaculate, alternative methods such as urine collection
after retrograde ejaculation, rectal electroejaculation
under anesthesia and testicular sperm aspiration are an
option.
2. Hormonal gonadoprotection: hormonotherapy in
men is not recommended (Evidence IIID).














If treatment occurred prior to puberty:
BCNU (Carmustine) 1 g/m2
CCNU (Lomustine) 500 mg/m2
Medium risk Cisplatin
Doxorubicin
Bevacizumab (34% ovarian failure)







Temporary reduction in sperm count:
Adriamycin 770 mg/m2
Thiotepa 400 mg/m2









High risk AC 9 4,[40 years, 57–63%
CMF 9 6,[40 years, 79–96%




Medium risk CMF 9 6, 30–40 years, 31–38%
CAF/CEF 9 6,\30 years, 23–47%
DA-R-EPOCH,\35 years, 30%
CHOP 9 6
Low risk AC 9 4, 30–40 years, 13%




Modified from several sources: Azim et al [37], Meistrich [15]
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3. Other methods: testicular tissue or spermatogonial
cryopreservation and reimplantation or grafting of
human testicular tissue are still experimental. How-
ever, these approaches may be the only option of
fertility preservation available to prepubertal boys.
Methods to preserve fertility in females with cancer
Different methods to preserve fertility could be proposed
depending on patients’ age, current success rate, required
delay in cancer treatment, required ovarian stimulation,
sperm requirement and risk of reintroducing malignant
cells (Table 5) [20–22]:
1. Embryo cryopreservation: embryo cryopreservation
is a widely established method for female fertility
preservation, with a reported life birth rate of 44.4%
(Evidence IIA).
2. Oocyte cryopreservation: this is the preferent option
when embryo cryopreservation is not possible, partic-
ularly for patients without a male partner or have
religious or ethical objections to embryo freezing
(Evidence IIA). Oocyte cryopreservation can be done
either by conventional slow freezing or by vitrification.
Vitrification is now the most widely used method of
oocyte cryopreservation due to the improved survival
and fertilization rates, compared to slow freezing
method [23, 24].
3. Immature oocyte cryopreservation: the major limi-
tation of embryo and mature oocyte cryopreservation is
the time to complete ovarian stimulation. Immature
oocyte cryopreservation is not as successful as cryop-
reserving oocytes or embryos that have matured
in vivo and is considered experimental.
4. Ovarian tissue cryopreservation and transplanta-
tion: ovarian tissue cryopreservation involves harvest-
ing and freezing ovarian tissue, allowing preservation
of oocytes within primordial follicles. In the future, the
tissue can be autotransplanted or matured in vitro. This
procedure allows immediate initiation of cancer treat-
ment as it does not require prior ovarian stimulation
nor sperm donation. To date, there have been at least
60 live births after ovarian tissue transplantation [25]
(Evidence IIIB).
5. Ovarian protection with gonadotropin-releasing
hormone agonists (GnRHa): the role of GnRHa to
preserve ovarian function during chemotherapy has
been investigated in many randomized trials and 14
meta-analyses have been published [26]. Regarding
pregnancy outcomes, only nine meta-analyses investi-
gated this question and only three studies found a
positive impact of GnRHa on pregnancy outcomes.
The Prevention of Early Menopause Study (POEMS)
randomized 218 premenopausal women with early-
stage, receptor-negative breast cancer. The study
demonstrated a reduced incidence of ovarian failure
and higher rates of pregnancy with the administration
of GnRHa. However, other study reviewed the efficacy
of GnRHa use in lymphoma patiens [27] but not
benefit could be demonstrates. The use of GnRHa
could be an option to discuss with patients with early-
stage receptor negative breast cancer if embryo or
oocyte cryopreservation not feasible (Evidence IIB).
The use of GnRHa to preserve fertility in women with
other cancer should not be recommended (Evidence
IIB).










Success rates Special considerations
GnRHa No No No Controversial, just partially
recommended in ER-negative breast
cancer patient
Embryo freezing Yes Yes Yes Cumulative pregnancy rate of




Yes Yes No Pregnancy rate per cycle of







No No No Pregnancy rate of 25% among
women with cancer
No indication when high risk of
ovarian metastases
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Special concerns in breast and ovarian cancer
Women diagnosed with breast cancer have the lowest
chance of subsequent pregnancy which is nearly 70% lower
compared to the general population. This is believed to be
secondary to frequent treatment with gonadotoxic
chemotherapy, prolonged treatment periods with tamoxifen
in patients with endocrine-sensitive disease and also a
general misconception that pregnancy could stimulate
cancer recurrence being a hormonally driven disease [28].
Based on accumulating research, there does not appear
to be an increased risk of cancer recurrence in women as a
result of fertility preservation and pregnancy, including
those with hormonally sensitive tumors [29]. Conventional
ovarian stimulation causes supra-physiological estradiol
(E2) levels and, therefore, may be unsuitable for women
with estrogen receptor-positive (ER?) tumors. Instead,
ovulation induction regimens incorporating tamoxifen or
aromatase inhibitors (AIs) can be used resulting in atten-
uated E2 levels without compromising embryo or oocyte
viability. Additional fertility counseling for women who
have a BRCA1 or 2 mutation (or are at high risk of having)
is warranted to educate them about the available fertility
preservation options in the context of their unique con-
cerns. Women with BRCA mutations may elect to use
preimplantation genetic diagnosis during in vitro fertiliza-
tion to avoid transmitting the mutation [30] (Table 6).
About 7% of epithelial ovarian cancer (EOC) patients
are diagnosed under 40 and 2% of those are even younger
than 30 years of age. In young patients having desire to
preserve fertility, conservative strategies could be applied,
consisting in conservative surgical approaches as unilateral
salpingo-oophorectomy on the side of the tumor and opti-
mal surgical staging [31]. The majority of guidelines sug-
gest a conservative approach in stage IA–B and grade 1
tumors and non-clear cell histology. Data regarding stage
IC or stage IA–B grade III are too far limited. Conservative
surgery should be avoided in stage IB and IC tumors with
bilateral involvement.
Malignant ovarian germ cell tumors (MOGCT) repre-
sent 5% of all ovarian neoplasms. Cisplatin-based regimens
are now preferred because they seem to offer a better fer-
tility outcome than non-cisplatin-based chemotherapies.
Fertility-sparing surgery may be the standard treatment in
young patients with early-stage BOTs [32].
Preservation Ferlitity Options in Prepubertal
Patients
There are new observational and case studies addressing
fertility preservation of children and adolescents with
cancer, including the risks of radiation as well as
chemotherapy. Current techniques are limited by the
patient’s sexual immaturity and all available approaches
for children are experimental [17].
Females
For prepubertal patients, we recommend to use established
methods of fertility preservation (gonadal tissue cryop-
reservation, radiation shielding or ovarian transposition),
with patient assent and parent consent [17].
Ovarian tissue cryopreservation followed by heterotopic
implantation (e.g., in the abdominal wall, forearm, chest
wall) or orthotopic implantation (e.g., to remaining ovarian
tissue or pelvic peritoneum), after the end of oncologic
treatment, is an investigational approach. No reports of live
births after ovarian cortical tissue cryopreserved prepu-
bertally and reimplanted at a later date, primarily because
Table 6 Pregnancy in LSV
Situation Proposed action
Increase risk of immediate and later health complications Cancer patients should be informed before starting anticancer
treatment
Potential risk of pregnancy for themselves and their offsprings Patients should be aware about risk of cancer recurrence, difficulty in
early cancer detection during pregnancy and hereditary syndromes
Increased risk of miscarriages in patients with pelvic irradiation Stop smoking, because increase incidence or miscarriages in this
situation
No different physical conditions or about life style have been related
with adverse pregnancy outcomes
No definitive dates. Research should be continued
High dose of alkylating drugs and cisplatin Decreased likelihood of siring a pregnancy in male survivors of
childhood cancer
Incidence of potential obstetric and offspring risks of morbid conditions
associated with anticancer treatment as well as fertility preservation
options in cancer survivors
Medical professionals should be properly trained
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of the young age of the study participants [33] (Evidence
IVB).
Males
Due to the fact that active spermatogenesis only starts from
puberty onwards, prepubertal boys cannot benefit from
sperm cryopreservation. A potential alternative strategy for
preserving their fertility involves storage of immature
gametes and gonadal stem cells after testicular tissue
sampling in the hope that future technologies will allow its
safe utilization [18, 34]. Although prepubertal testicular
stem cell banking is being introduced into clinical practice,
this approach should be regarded as experimental in view
of the paucity of evidence of successful transplantation and
the scarce safety data for this method [18] (Evidence VB).
There is no role for gonadal protection by any form of
hormonal or pharmacological means in either boys or girls
[16] (Evidence IIIB).
Pregnancy in LSV: recommendations
Albeit studies analyzing the effect of previous anticancer
treatments (chemotherapy, radiotherapy, surgery and/or
hematopoietic stem cell transplant) on pregnancy and
livebirth are not enough, important reviews have been
published (Table 6). One of them [10] observed that greater
doses of contemporary alkylating drugs and cisplatin were
associated with a decreased likelihood of siring a preg-
nancy in male survivors of childhood cancer.
Other investigator’s group [35] evaluates the associa-
tions between pre-pregnancy lifestyle factors, psychologic
distress, and adverse pregnancy outcomes in a large cohort
of 1192 female survivors of childhood cancer. This study
concluded that the risk for miscarriage was significantly
increased among survivors exposed to [2.5 Gy uterine
radiation who had a history of smoking.
Tarı´n et al. [36] observed that exist different morbid
conditions associated with anticancer therapies, as thyroid
dysfunction, hyperprolactinemia, hyperglycemia or hyper-
tension, may be risk factors for pregnancy or offspring.
Diagnosis and treatment of thyroid dysfunction
before/during pregnancy may prevent or alleviate the
effects of maternal thyroid disease on early brain devel-
opment. Likewise, untreated hyperprolactinemia may be a
risk factor for ectopical pregnancy.
Maternal age at childbirth is steadily rising in many
Western populations, and female cancer survivors are not
an exception to this general trend. The resulting obstetric
and offspring risks associated with postponed maternity
may be superimposed on those already present in cancer
survivors.
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